Why Turning Point Brands Stock Crushed it on Thursday

Turning Point Brands posted Q2 net sales of $124.3 million, up nearly 17% year over year and above the $123.8 million consensus, while adjusted EPS of $0.76 also beat the $0.59 estimate. Stoker smokeless sales surged 48% to $87.6 million, offset by a 22% decline in Zig-Zag to $36.7 million, and management raised 2026 modern oral guidance to $210 million-$225 million from $180 million-$190 million. The stock rose more than 11% as investors focused on the stronger smokeless growth outlook.

Analysis

The market is re-rating TPB less on the headline beat than on the composition of growth: modern oral is now large enough to change the earnings mix, which matters because it is a higher-quality, more repeatable consumption trend than the legacy rolling-paper base. That creates a second-order effect: as the modern oral mix rises, margin volatility should fall and valuation can expand from a "small-cap vice retailer" multiple toward a more stable consumables multiple, even if the top line remains modest versus big tobacco.

The key debate is duration. If pouch adoption is still in an early penetration phase, the current guide raise likely understates the 12-18 month earnings power because distribution gains and repeat purchase behavior tend to compound after initial trial. But Zig-Zag weakness is a warning that TPB is not getting a free macro tailwind; the stock can stay range-bound if the legacy decline accelerates faster than modern oral scales, especially if retail shelf space gets reallocated by larger competitors with stronger trade budgets.

Consensus may be underestimating how asymmetric this is versus BTI. TPB does not need a category-wide nicotine growth story to work; it only needs modern oral to keep taking share and to offset the drift in legacy products. The contrarian risk is that the current move already prices in a clean handoff, while the actual path is likely choppier over the next 1-2 quarters as investors probe whether the new guidance is sustainable or just a one-quarter acceleration.

Key Decisions for Investors

• Long TPB on pullbacks over the next 2-6 weeks; target a 15-20% upside move if the market starts capitalizing the upgraded 2026 modern-oral guide as more durable than a one-quarter beat. Use a tight stop if the stock gives back the post-earnings gap, since the setup is momentum-sensitive.
• Pair trade: long TPB / short BTI for 1-3 months. The thesis is that TPB has cleaner category-specific growth optionality, while BTI remains a slower multiple story tied to legacy business optics; risk is BTI catching a rerating if dividend buyers rotate back into defensives.
• Sell cash-secured puts on TPB at strikes roughly 10-15% below spot with 30-45 day expiry to express a bullish-to-neutral view. This works if you think the post-earnings volatility is still elevated and the market will pay you to own the stock on any digestion phase.
• If already long TPB, trim into strength and re-add only on confirmation of next-quarter modern oral sell-through. The risk/reward improves if management proves the guide raise is conservative, but near-term upside may be capped after the sharp initial reaction.